4//SEC Filing
Flynn Daniel Lee 4
Accession 0001209191-20-011040
CIK 0001654151other
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 4:10 PM ET
Size
8.5 KB
Accession
0001209191-20-011040
Insider Transaction Report
Form 4
Flynn Daniel Lee
Chief Scientific Officer
Transactions
- Award
Common Stock
2020-02-18+7,040→ 98,446 total - Award
Stock Option (Right to Buy)
2020-02-18−42,190→ 42,190 totalExercise: $54.87Exp: 2030-02-17→ Common Stock (42,190 underlying)
Holdings
- 91,020(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]The reporting person was awarded 7,040 Restricted Stock Units under the 2017 Stock Option and Incentive Plan. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in equal 25% installments on February 15, 2021, February 15, 2022, February 15, 2023 and February 15, 2024, subject to continued service through such dates. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
- [F2]This stock option award was issued pursuant to Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments over a 4-year period following the vesting commencement date of 2/18/2020, subject to continued service through such dates.
Documents
Issuer
Deciphera Pharmaceuticals, Inc.
CIK 0001654151
Entity typeother
Related Parties
1- filerCIK 0001713712
Filing Metadata
- Form type
- 4
- Filed
- Feb 19, 7:00 PM ET
- Accepted
- Feb 20, 4:10 PM ET
- Size
- 8.5 KB